Welcome to our dedicated page for Cti Biopharma news (Ticker: CTIC), a resource for investors and traders seeking the latest updates and insights on Cti Biopharma stock.
CTI BioPharma Corp. (CTIC), now part of Swedish Orphan Biovitrum (Sobi), remains a key innovator in targeted cancer therapies following its 2023 acquisition. This page provides essential updates about the company's ongoing operations, therapeutic developments, and integration with Sobi's rare disease expertise.
Investors and healthcare professionals will find timely updates on VONJO® (pacritinib) advancements, post-merger strategic initiatives, and regulatory milestones. Our curated news feed covers earnings reports, clinical trial progress, and partnership developments while maintaining strict compliance with financial disclosure standards.
Key focus areas include updates on CTIC's unique JAK2-sparing approach to blood cancer treatment, integration updates with Sobi's global infrastructure, and therapeutic pipeline developments. Bookmark this page for verified updates about one of biopharma's most significant recent mergers and its implications for cancer care innovation.
CTI BioPharma Corp. (Nasdaq: CTIC) announced its participation in two key investor conferences in April 2023, aimed at discussing its novel targeted therapies for blood-related cancers. The company will engage in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 3:45 p.m. ET, and will present at the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 1:00 p.m. ET. Live and archived webcasts can be accessed through the CTI BioPharma website. CTI BioPharma is also noted for its FDA-approved product, VONJO® (pacritinib), which targets myelofibrosis patients with low platelet counts.
CTI BioPharma Corp. (Nasdaq: CTIC) announced on April 10, 2023, that its Compensation Committee granted equity inducement awards to two new employees. This was done under Nasdaq Listing Rule 5635(c)(4) and outside of the company's Amended and Restated 2017 Equity Incentive Plan.
The awards totaled options for 36,000 shares of CTIC common stock, with an exercise price equal to the closing price on each grant date. The options will vest over four years, contingent on continued employment, and are valid for a ten-year term.
CTI BioPharma focuses on targeted therapies for blood-related cancers and has one FDA-approved product, VONJO (pacritinib), aimed at treating patients with specific myelofibrosis conditions.
FAQ
What is the market cap of Cti Biopharma (CTIC)?
